Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies.
Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies.
复制标题
DOI：
10.3389/fneur.2020.00778
复制
发表时间：
2020
影响因子：
3.4
通讯作者：
Paul F
中科院分区：
文献类型：
--
作者：
Asseyer S;Cooper G;Paul F
视神经脊髓炎谱系疾病 (NMOSD) 和髓磷脂少突胶质细胞糖蛋白抗体相关疾病 (MOGAD) 是中枢神经系统 (CNS) 的自身免疫性炎症性疾病。 NMOSD 和 MOGAD 中的疼痛非常普遍，并且使人衰弱，严重影响生活质量，迫切需要进一步研究以成功治疗和控制这些罕见疾病的疼痛。在 NMOSD 中，疼痛的患病率超过 80%，疼痛综合征包括神经性疼痛、伤害性疼痛和混合性疼痛，这些疼痛可在急性复发时出现，也可在病程中转为慢性。 MOGAD 疼痛的影响最近才受到越来越多的关注，估计患病率超过 70%。这些患者通常不仅会经历严重头痛、球后疼痛和/或视神经炎引起的眼球运动疼痛，而且还会经历神经性疼痛和伤害性疼痛。鉴于 MOGAD 和 NMOSD 中疼痛的高度相关性，本文对当前有关这两种疾病疼痛的文献进行了系统回顾，重点关注其各自疼痛综合征的病因学及其病理生理学背景。认识到诊断疼痛的挑战和复杂性，我们还提供了 NMOSD 和 MOGAD 相关疼痛综合征的基于机制的分类，并总结了当前的治疗策略。
Neuromyelitis optica spectrum disorders (NMOSDs) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) are autoimmune inflammatory disorders of the central nervous system (CNS). Pain is highly prevalent and debilitating in NMOSD and MOGAD with a severe impact on quality of life, and there is a critical need for further studies to successfully treat and manage pain in these rare disorders. In NMOSD, pain has a prevalence of over 80%, and pain syndromes include neuropathic, nociceptive, and mixed pain, which can emerge in acute relapse or become chronic during the disease course. The impact of pain in MOGAD has only recently received increased attention, with an estimated prevalence of over 70%. These patients typically experience not only severe headache, retrobulbar pain, and/or pain on eye movement in optic neuritis but also neuropathic and nociceptive pain. Given the high relevance of pain in MOGAD and NMOSD, this article provides a systematic review of the current literature pertaining to pain in both disorders, focusing on the etiology of their respective pain syndromes and their pathophysiological background. Acknowledging the challenge and complexity of diagnosing pain, we also provide a mechanism-based classification of NMOSD- and MOGAD-related pain syndromes and summarize current treatment strategies.
登录
查看更多内容
DOI：
10.1212/nxi.0000000000000131
发表时间：
2015-08
期刊：
Neurology(R) neuroimmunology & neuroinflammation
影响因子：
--
作者：
Chalmoukou K;Alexopoulos H;Akrivou S;Stathopoulos P;Reindl M;Dalakas MC
通讯作者：
Dalakas MC
影响因子：
9.9
作者：
Araki M;Matsuoka T;Miyamoto K;Kusunoki S;Okamoto T;Murata M;Miyake S;Aranami T;Yamamura T
通讯作者：
Yamamura T
影响因子：
3.4
作者：
Borisow N;Mori M;Kuwabara S;Scheel M;Paul F
通讯作者：
Paul F
DOI：
10.1177/2055217318796684
发表时间：
2018-07
影响因子：
--
作者：
Asseyer S;Schmidt F;Chien C;Scheel M;Ruprecht K;Bellmann-Strobl J;Brandt AU;Paul F
通讯作者：
Paul F
影响因子：
168.9
作者：
Carr, DB;Goudas, LC
通讯作者：
Goudas, LC